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Objectives. This study sought to assess the potential association
of the angiotensin-converting enzyme (ACE) and angiotensin II
type 1 (AT1) receptor gene polymorphisms on coronary vasomo-
tion in humans.
Background. Abnormal coronary vasomotion plays a role in the
clinical expression of coronary atherosclerosis. The components
of the renin–angiotensin system are important determinants of
vasomotor tone. Furthermore, epidemiologic evidence suggests
that these components are involved in the pathogenesis of coro-
nary artery disease. Indeed, two genetic polymorphisms of the
ACE and AT1 receptor genes were synergistically associated with
the occurrence of myocardial infarction. The influence of these
genetic polymorphisms on the risk of myocardial infarction may
be related, at least in part, to a deleterious effect on coronary
vasomotion.
Methods. We studied the response of angiographically normal
human coronary arteries after intravenous injection of methyler-
gonovine maleate, a potent vasoconstrictor whose effects have
been previously explored in various aspects of coronary artery
disease. We characterized the ACE and AT1 receptor genotypes in
a consecutive series of 140 patients with normal coronary arteries.
Coronary vasomotion was assessed with quantitative coronary
angiography.
Results. No effect of the ACE gene polymorphism was detected.
Conversely, the patients carrying the AT1 receptor CC genotype
(n 5 13) had significantly greater vasoconstriction in distal
coronary vessels (p < 0.009).
Conclusions. The AT1 receptor gene polymorphism is associ-
ated with coronary vasomotion in humans.
(J Am Coll Cardiol 1997;29:486–90)
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The clinical manifestations of coronary artery disease are not
linearly related to the extent of coronary atherosclerosis.
Indeed, acute myocardial infarction generally occurs at athero-
sclerotic plaques that do not significantly narrow the coronary
artery lumen (1). The ultimate step in the pathogenesis of
acute myocardial infarction is the formation of occlusive
thrombus in a coronary artery at the site of a ruptured
atherosclerotic plaque (2); however, evidence of plaque rup-
ture is common at autopsy in patients dying of noncardiac
causes, suggesting that plaque rupture is a necessary but not
the sole factor involved in coronary artery occlusion (3).
Intense vasoconstriction at the site of plaque rupture may also
be an important contributory factor; direct evidence that this is
so has been provided by angiographic observations during
acute infarction (4).
The components of the renin–angiotensin system, involved
in blood pressure regulation and vascular smooth muscle cell
proliferation, are important determinants of vasomotor tone
(5). Angiotensin-converting enzyme (ACE), a key component
of the renin–angiotensin system, is involved in the generation
of angiotensin II, a potent vasoconstrictor peptide, and in the
degradation of bradykinin, a potent vasodilator (6). The circu-
lating and cellular levels of ACE are partly genetically deter-
mined through the insertion/deletion polymorphism of the
gene coding for ACE (ACE) (7,8). Subjects bearing the ACE
deletion (D) allele have a higher level of circulating enzymes
than subjects bearing the insertion (I) allele. Recent studies
(9–11) have suggested that ACE D allele bearers may have a
higher risk of myocardial infarction and sudden death.
The effects of angiotensin II are exerted through the activa-
tion of specific high affinity receptors. Most of the cardiovas-
cular effects of angiotensin II are mediated by the angiotensin
II type 1 (AT1) receptor, expressed by vascular smooth muscle
cells (12). Recently, a polymorphism located in the 39 untrans-
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lated region of the AT1 receptor gene (AT1) (corresponding to
an adenine/cytosine (A/C) base substitution at the 1166 posi-
tion) has been shown (13) to modify the association of the I/D
ACE polymorphism with the occurrence of myocardial infarc-
tion. The AT1 receptor C allele increased synergistically the
risk of myocardial infarction in subjects carrying the ACE D
allele. The interaction of these two genetic susceptibility risk
factors on the occurrence of myocardial infarction could be
related to a deleterious effect on coronary vasomotion. To
explore this hypothesis, we analyzed the vasomotor responses
of angiographically normal coronary arteries to methylergono-
vine maleate, the most commonly used vasoconstrictor stimu-
lus in clinical practice (14), and to isosorbide dinitrate (ISDN),
an endothelium-independent smooth muscle dilator.
Methods
Patients. We studied patients admitted for diagnostic cor-
onary angiography who were found to have an angiographically
normal coronary tree. The study included 140 such patients
recruited consecutively. Age, gender, body mass index, family
and personal history of coronary artery disease, and drug and
tobacco consumption were recorded. Total cholesterol and
triglyceride plasma levels were measured by enzymatic meth-
ods (Boehringer Mannheim, Germany) adapted to a Hitachi
717 analyzer. Patients with dilated cardiomyopathy or a history
of myocardial infarction or who had valvular heart disease
were excluded.
Angiography and provocative testing. All drugs were dis-
continued 48 h before angiography. After diagnostic coronary
angiography, an appropriate view of a coronary artery was
selected, and a baseline arteriogram was obtained. Methyler-
gonovine maleate (100 mg) was injected intravenously, and an
angiogram was obtained 3 min later. An additional dose of
methylergonovine maleate (300 mg) was then injected, and
another angiogram was recorded 3 min later. After that,
200 mg of ISDN was injected into the coronary artery, and
another angiogram was recorded 2 min later. Finally, 2 mg of
ISDN was injected into the coronary artery, and a final
angiogram was recorded 2 min later.
Quantitative coronary angiographic analysis. The coro-
nary angiograms were analyzed with the CAESAR System
(Computer Assisted Evaluation of Stenosis and Restenosis), a
computerized automatic analysis system (15). The angio-
graphic catheter was used for calibration. The mean diameters
of proximal and distal segments, identified by their distance
from side branches or from the origin of the vessel, were
determined. Maximal response to methylergonovine maleate
and ISDN was expressed relative to baseline diameter after
300 mg of methylergonovine maleate and 2 mg of ISDN,
according to the formula: Maximal constriction by 300 mg of
methylergonovine maleate 5 [(Diameter after ergonovine 2
Baseline diameter)/Baseline diameter] 3 100 (%), and Maxi-
mal dilation by 2 mg of ISDN 5 [(Diameter after ISDN 2
Baseline diameter)/Baseline diameter] 3 100 (%).
Genetic analyses. Genomic DNA was extracted from white
blood cells. The ACE fragment (8) containing the I/D sequence
and AT1 receptor fragment (13) containing the A/C 1166
substitution were amplified with a Perkin Elmer DNA thermal
cycler and Thermus aquaticus DNA polymerase (Amersham).
The ACE polymorphism was detected as previously described,
except for addition of dimethylsulfoxide to enhance amplifica-
tion of the ACE I allele (16). The AT1 receptor A/C polymor-
phism was analyzed by allele-specific oligonucleotide hybrid-
izations after amplification (13).
Statistical analyses. Statistical analyses were performed
with the SAS Software release 6.10 (SAS Institute Inc.). Mean
value 6 SD were calculated; error of the mean (SEM) was
used to plot quantitative data. Quantitative variables were
compared according to the ACE genotypes (i.e., II, ID, DD)
and the AT1 receptor genotypes (i.e., AA, AC, CC). Given the
unequal number of observations for each group of genotype,
we performed an analysis of variance within the framework of
general linear models (GLM procedure). This GLM procedure
was also used to conduct a multivariate analysis of covariance
to take into account the potential effect of quantitative and
qualitative confounding factors, and to test for interaction
(crossed effects) between the two polymorphisms. A synergistic
effect between the two genetic variables was tested by including
both variables simultaneously in the model together with the
interaction between the ACE and AT1 receptor genotypes. In
these multivariate models, the normal distribution of the
residues was verified; the estimate of the coefficients and
standard errors from the multivariate analysis were computed
for each variable. The genetic variables were tested with 2
degrees of freedom. Significance levels were set at p , 0.01.
Results
Patients. Sixty-eight percent of our patients were male and
had a mean age of 54 6 10 years; 27% were smokers; 12% had
diabetes mellitus; 48% had systemic hypertension; and 41%
had a family history of coronary artery disease. The frequen-
cies of the ACE D and I alleles were 0.57 and 0.43, respectively;
the frequencies of the AT1 receptor A and C alleles were 0.70
and 0.30, respectively. These frequencies were close to values
reported in other white patient groups (9,13). Genotype dis-
tributions of both polymorphisms were in Hardy-Weinberg
equilibrium. Proximal and distal baseline segment diameters
were similar among the different groups of genotypes (Table
1). In the whole cohort, proximal and distal segments con-
stricted in response to methylergonovine maleate and relaxed
Abbreviations and Acronyms
A/C 5 adenine/cytosine
ACE 5 angiotensin-converting enzyme
AT1 5 angiotensin II type 1 receptor
GLM 5 general linear models
I/D 5 insertion/deletion
ISDN 5 isosorbide dinitrate
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after ISDN. No patient developed occlusive epicardial spasm.
No differences in vasoconstrictor or vasodilator responses were
observed in subgroups with different ACE genotypes (Fig. 1).
However, patients who had the AT1 receptor CC genotype had
significantly greater maximal vasoconstriction (p , 0.009) in
distal coronary segments than patients with the AA or AC
genotypes (22.9%, 11.3% and 11.5%, respectively) (Fig. 2).
This enhanced constriction was independent (adjusted test,
p 5 0.008) of age, gender, family history of coronary heart
disease, plasma lipid levels, diabetes, systemic hypertension
and cigarette consumption (Table 2). Maximal vasodilation in
response to ISDN did not differ among the different groups of
Figure 1. Vasoreactivity of proximal and distal coronary segments
according to ACE genotypes. Max. 5 maximal.
Figure 2. Vasoreactivity of proximal and distal coronary segments
according to AT1 receptor genotypes. Max. 5 maximal. *adjusted test,
p 5 0.008.
Table 1. Baseline Diameters of Proximal and Distal Coronary Segments as a Function of ACE and AT1 Receptor Genotypes
ACE Genotypes AT1 Receptor Genotypes
II
(n 5 27)
ID
(n 5 67)
DD
(n 5 46)
AA
(n 5 67)
AC
(n 5 60)
CC
(n 5 13)
Proximal segment (mm) 3.43 6 0.72 3.31 6 0.77 3.49 6 0.84 3.32 6 0.80 3.44 6 0.77 3.54 6 0.78
Distal segment (mm) 2.33 6 0.54 2.44 6 0.65 2.31 6 0.50 2.35 6 0.61 2.39 6 0.57 2.45 6 0.47
Data presented are mean value 6 SD. A 5 adenine; ACE 5 angiotensin-converting enzyme; AT1 5 angiotensin II type 1 receptor; C 5 cytosine; D 5 deletion;
I 5 insertion.
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genotypes. No significant association between the AT1 recep-
tor genotypes and systemic hypertension existed in this sample.
No significant interaction on coronary vasomotion could be
detected between ACE and AT1 receptor genotypes.
Discussion
Our results suggest that subjects with the AT1 receptor CC
genotype had an exaggerated constrictor response to methyl-
ergonovine maleate, a vasoconstrictor agent used to explore
coronary vasomotion in clinical practice. By contrast, no effect
of the ACE genotype on coronary vasomotion could be de-
tected.
These results are at variance with those of a Japanese study
(17) reporting that the ACE but not the AT1 receptor poly-
morphism was associated with coronary artery spasm. Al-
though Japanese study and ours relate to coronary vasomotion,
they addressed different issues in a different ethnic back-
ground. Indeed, the case-control study developed by Oike et al.
(17) recruited specific contrasted groups of patients: The cases
presented a total occlusive spasm during ergonovine provoca-
tion and significant ST segment alterations, whereas the con-
trols had no reaction after the provocative test. Conversely,
none of our patients developed occlusive spasm. Moreover, the
normal distributions of the vasomotor tone indexes allowed us
to perform a quantitative analysis. The differences in ethnic
background may also account for the different results: In the
Japanese study, the ACE D allele frequency was 0.36, consis-
tent with other Japanese reports (18) but significantly lower
than those in white patients (0.56) (9). The frequency reported
in the Japanese cohort for the C allele of the AT1 receptor was
0.09, significantly lower than that observed in white patients
(0.30) (13). Finally, the AT1 receptor CC genotype was totally
absent in the Japanese study, and consequently, its effect on
vasomotion could not be tested.
Potential mechanisms. We previously reported (14) the
effects of methylergonovine maleate on the coronary circula-
tion in patients with diverse clinical manifestations of coronary
artery disease. Localized segmental hypereactivity in the
infarct-related vessel was observed in 20% of patients with
recent myocardial infarction. The influence of the AT1 recep-
tor CC genotype on coronary artery vasomotion in response to
methylergonovine maleate may be related to an effect on
smooth muscle cells. Methylergonovine maleate has a direct
constrictor effect on vascular smooth muscle cells due to a
stimulant effect on alpha-adrenergic and serotoninergic recep-
tors (19). These arterial smooth muscle cells express AT1
receptors that mediate most of the known vascular effects of
angiotensin II, a potent vasoconstrictor peptide (12).
In our patients, the influence of the AT1 receptor polymor-
phism on coronary vasomotion was observed predominantly in
distal coronary segments. This observation is consistent with
previous studies (20) that have documented a heterogeneous
response in the coronary tree to vasoactive stimuli: Distal
coronary segments have greater vasoreactivity in response to
ergonovine and nitrates than proximal segments.
This influence on coronary vasoconstriction was observed in
subjects homozygous for the C allele of the AT1 receptor
polymorphism, suggesting a recessive effect. Conversely, no
effect of ACE gene polymorphism on coronary vasomotion was
detected. However, because methylergonovine maleate pre-
dominantly acts through endothelium-independent direct
smooth muscle cell constriction (19), we cannot exclude an
effect of the ACE genotype on endothelium-dependent re-
sponses.
A recent study (21) described an increased frequency of the
AT1 receptor C allele in subjects with essential hypertension.
We were not able to detect this association in our sample.
Given the small effect reported for this polymorphism on
hypertension, our study was lacking statistical power to draw
any conclusion. However, the enhanced vasoconstriction asso-
ciated with the AT1 receptor polymorphism may partly account
for high blood pressure levels in C allele bearers. A recent
report (22) has associated the AT1 receptor CC genotype with
aortic stiffness in hypertensive patients. Our observation of
increased vasoconstriction in AT1 receptor CC genotype bear-
ers could support the hypothesis that this increased aortic
Table 2. Multivariate Analysis of Maximal Vasoconstriction on AT1 Receptor Genotypes
and Covariables
Independent Variable Coefficient SE df F Value p Value
Age (yr) 20.13 0.13 1 1.11 0.294
Male gender 7.18 3.53 1 4.15 0.044
Family history of CAD 21.01 2.48 1 0.17 0.685
Total cholesterol (g/liter) 4.19 2.98 1 1.98 0.162
Triglycerides (g/liter) 21.50 0.87 1 2.96 0.088
Diabetes 20.80 3.82 1 0.04 0.835
Systemic hypertension 22.03 2.42 1 0.70 0.403
Smoking status 25.28 3.37 1 2.45 0.120
AT1 receptor genotype
CC 12.84 4.05 2 5.11 0.008
AC 1.44 2.50
CAD5 coronary artery disease; df5 degrees of freedom; SE5 standard error of the coefficient; other abbreviations
as in Table 1.
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stiffness may reflect an excessive constrictor response of sys-
temic resistance vessels in such patients.
Conclusions. The present study demonstrates that the AT1
receptor genotype is associated with exaggerated coronary
vasoconstriction. Given the low frequency of the C allele and
CC genotypes in human populations, further investigations are
needed to confirm these results and to clarify the possible
mechanisms involved in this phenomenon. In particular, it is
important to differentiate between a direct but less probable
role of the AT1 receptor C1166 mutation and a strong linkage
disequilibrium of this polymorphism with a causal variant
(13,23). However, this observation might explain, at least in
part, the synergistic effect of this genetic polymorphism to-
gether with the ACE I/D polymorphism on the occurrence of
myocardial infarction.
We thank Claudine Mercier and Vale´rie Codron for excellent scientific and
technical assistance.
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